Wegovy for Overweight Young Children: Novo Nordisk’s Obesity Drug Shows Effectiveness
Novo Nordisk Phase 3 STEP Young trial shows once-weekly semaglutide reduced BMI in 40.4% of children with obesity after 68 weeks.
Share
Why It Matters
Novo Nordisk's obesity medicine worked better than a fake medicine for overweight kids in a big test. This is good news for the company because it might be able to sell this medicine to more people soon.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.